Developing a new treatment for non-small cell lung cancer and other solid tumors
Official title: VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors
Funded at Velorum Therapeutics INC. · NIH-11066672 · Data updated 2026-11-12
This study is testing a new treatment called VEL-03 for people with non-small cell lung cancer, which aims to help fight the cancer while being gentle on healthy cells, and it will be used alongside radiation and a common chemotherapy drug to see if it can improve results for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Velorum Therapeutics INC. NIH-funded |
| Lab location | 1 site (Plano, United States) |
| Project start | June 3, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $772,293 |
| NIH project number | 1R44CA291444-01A1 |
| Project ID | NIH-11066672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer or other solid tumors who have limited treatment options.
✕Less likely to help
Patients with early-stage cancers or those who do not have solid tumors may not benefit from this research.
What this research studies
This research focuses on a novel therapy called VEL-03, designed to target the metabolism of cancer cells, particularly in non-small cell lung cancer (NSCLC). The approach involves disrupting heme uptake, which is crucial for cancer growth, while minimizing damage to normal cells. The study will evaluate the effectiveness of VEL-03 in combination with radiation therapy and Cisplatin, and will also work on scaling up the manufacturing process for clinical use. Patients may benefit from this innovative treatment that aims to improve outcomes for those with hard-to-treat cancers.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with non-small cell lung cancer and other solid tumors.
How similar studies have gone: Other research has shown promise in targeting cancer metabolism, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
-
Velorum Therapeutics INC.
Plano, United States Active
Researchers
- Principal investigator: Showalter, Richard Edward — Velorum Therapeutics INC.
- Study coordinator: Showalter, Richard Edward
Related research
Other NIH-funded projects on the same topics.
-
VEL-03: a new treatment approach for lung cancer and other solid tumors
A new drug candidate called VEL-03 aims to slow or stop the growth of non-small cell lung cancer and other solid tumors by targeting cancer cell metabolism.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.